iTeos Posts New Preclinical Data For Anti-TIGIT Antibody At ASH 2021

ITeos Therapeutics Inc ITOS posted new preclinical data for its anti-TIGIT monoclonal antibody, EOS-448, at the American Society of Hematology (ASH) Annual Meeting & Exposition and the TIGIT Therapies Digital Summit 2021.

• Data at the ASH 2021 demonstrated the efficacy of EOS-448 as a single agent and in combination with an immunomodulatory imide drug (IMiD) in a preclinical model of multiple myeloma. 
• The Fc-enabled anti-TIGIT monoclonal antibody elicited effective control of multiple myeloma disease progression, while an Fc-disabled version was inactive.
• Furthermore, the Fc-enabled anti-TIGIT antibody demonstrated synergistic activity when combined with an IMiD.
• Preclinical data shared at TIGIT Therapies Digital Summit highlight evidence for a multifaceted mechanism of action of EOS-448.
• "We look forward to progressing our clinical development plan in 2022 in both multiple myeloma and solid tumors with several combinations," said Michel Detheux, President & CEO.
• Related Link: iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK.
• Price Action: ITOS closed 1.38% lower at $34.26 on Thursday.